ZA200308779B - Novel ligand for nicotinic acetylcholine receptors useful in therapy. - Google Patents

Novel ligand for nicotinic acetylcholine receptors useful in therapy. Download PDF

Info

Publication number: ZA200308779B
Authority: ZA; South Africa
Prior art keywords: treatment; composition; compound; prophylaxis; substance
Prior art date: 2001-06-01

Application number

ZA200308779A

Other languages

English (en)

Inventor

Eifion Phillips

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-01

Filing date

2003-11-11

Publication date

2005-02-11

2003-11-11 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-02-11 Publication of ZA200308779B publication Critical patent/ZA200308779B/en

Links

238000002560 therapeutic procedure Methods 0.000 title claims abstract description 6
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 title claims description 21
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 title claims description 21
239000003446 ligand Substances 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 48
150000003839 salts Chemical class 0.000 claims abstract description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
238000011282 treatment Methods 0.000 claims description 36
208000035475 disorder Diseases 0.000 claims description 30
238000011321 prophylaxis Methods 0.000 claims description 29
238000000034 method Methods 0.000 claims description 28
230000006735 deficit Effects 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 22
239000003814 drug Substances 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 11
208000024827 Alzheimer disease Diseases 0.000 claims description 10
208000028017 Psychotic disease Diseases 0.000 claims description 10
229960002715 nicotine Drugs 0.000 claims description 10
208000019901 Anxiety disease Diseases 0.000 claims description 9
208000002193 Pain Diseases 0.000 claims description 9
208000018737 Parkinson disease Diseases 0.000 claims description 9
208000000323 Tourette Syndrome Diseases 0.000 claims description 9
208000016620 Tourette disease Diseases 0.000 claims description 9
230000036506 anxiety Effects 0.000 claims description 9
201000010099 disease Diseases 0.000 claims description 9
201000000980 schizophrenia Diseases 0.000 claims description 9
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 8
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 8
208000020925 Bipolar disease Diseases 0.000 claims description 8
208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 8
206010009900 Colitis ulcerative Diseases 0.000 claims description 8
208000023105 Huntington disease Diseases 0.000 claims description 8
208000001456 Jet Lag Syndrome Diseases 0.000 claims description 8
206010026749 Mania Diseases 0.000 claims description 8
206010057852 Nicotine dependence Diseases 0.000 claims description 8
208000025569 Tobacco Use disease Diseases 0.000 claims description 8
201000006704 Ulcerative Colitis Diseases 0.000 claims description 8
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 8
208000028683 bipolar I disease Diseases 0.000 claims description 8
230000001713 cholinergic effect Effects 0.000 claims description 8
230000007278 cognition impairment Effects 0.000 claims description 8
208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 8
208000015122 neurodegenerative disease Diseases 0.000 claims description 8
230000036407 pain Effects 0.000 claims description 8
230000000391 smoking effect Effects 0.000 claims description 8
210000000225 synapse Anatomy 0.000 claims description 8
208000000044 Amnesia Diseases 0.000 claims description 7
208000026139 Memory disease Diseases 0.000 claims description 7
230000004913 activation Effects 0.000 claims description 7
230000003935 attention Effects 0.000 claims description 7
230000009286 beneficial effect Effects 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
230000006984 memory degeneration Effects 0.000 claims description 7
208000023060 memory loss Diseases 0.000 claims description 7
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 6
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 4
239000000126 substance Substances 0.000 claims 14
230000002265 prevention Effects 0.000 claims 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
230000027455 binding Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000000047 product Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
229920002873 Polyethylenimine Polymers 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000556 agonist Substances 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
-1 heterocyclic amines Chemical class 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
239000003365 glass fiber Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
230000005062 synaptic transmission Effects 0.000 description 2
229930182840 (S)-nicotine Natural products 0.000 description 1
ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
102000009660 Cholinergic Receptors Human genes 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
229960004484 carbachol Drugs 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000002026 chloroform extract Substances 0.000 description 1
230000006949 cholinergic function Effects 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
150000002148 esters Chemical group 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
DWYMPOCYEZONEA-UHFFFAOYSA-L fluoridophosphate Chemical compound [O-]P([O-])(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-L 0.000 description 1
CYEFKCRAAGLNHW-UHFFFAOYSA-N furan-3-ylboronic acid Chemical compound OB(O)C=1C=COC=1 CYEFKCRAAGLNHW-UHFFFAOYSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
239000011539 homogenization buffer Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000472 muscarinic agonist Substances 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000004112 neuroprotection Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical compound OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000005586 smoking cessation Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
125000003003 spiro group Chemical group 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
239000004149 tartrazine Substances 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003643 water by type Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes

ZA200308779A 2001-06-01 2003-11-11 Novel ligand for nicotinic acetylcholine receptors useful in therapy. ZA200308779B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29520601P	2001-06-01	2001-06-01

Publications (1)

Publication Number	Publication Date
ZA200308779B true ZA200308779B (en)	2005-02-11

Family

ID=23136711

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200308779A ZA200308779B (en)	2001-06-01	2003-11-11	Novel ligand for nicotinic acetylcholine receptors useful in therapy.

Country Status (19)

Country	Link
EP (1)	EP1397366B1 (pt)
JP (1)	JP2004532877A (pt)
KR (1)	KR20040003021A (pt)
CN (1)	CN1294136C (pt)
AT (1)	ATE353332T1 (pt)
BR (1)	BR0210075A (pt)
CA (1)	CA2455341A1 (pt)
DE (1)	DE60218032T2 (pt)
DK (1)	DK1397366T3 (pt)
ES (1)	ES2280538T3 (pt)
HK (1)	HK1063787A1 (pt)
IL (1)	IL158735A0 (pt)
MX (1)	MXPA03010996A (pt)
NO (1)	NO20035333D0 (pt)
NZ (1)	NZ529426A (pt)
PT (1)	PT1397366E (pt)
SI (1)	SI1397366T1 (pt)
WO (1)	WO2002096912A1 (pt)
ZA (1)	ZA200308779B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
JP4511195B2 (ja) *	2002-04-18	2010-07-28	アストラゼネカ・アクチエボラーグ	フリル化合物
JP4511196B2 (ja)	2002-04-18	2010-07-28	アストラゼネカ・アクチエボラーグ	チエニル化合物
DE60328010D1 (de) *	2002-04-18	2009-07-30	Astrazeneca Ab	Heterocyclische verbindungen
JP4855264B2 (ja)	2003-10-21	2012-01-18	アストラゼネカ・アクチエボラーグ	スピロフロピリジンアリール誘導体
TW200813067A (en) *	2006-05-17	2008-03-16	Astrazeneca Ab	Nicotinic acetylcholine receptor ligands
SA08290475B1 (ar)	2007-08-02	2013-06-22	Targacept Inc	(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
AU2009260905B2 (en)	2008-06-20	2012-08-23	Astrazeneca Ab	Dibenzothiazepine derivatives and use thereof
TW201031664A (en)	2009-01-26	2010-09-01	Targacept Inc	Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
PT3029039T (pt)	2010-05-17	2017-11-28	Forum Pharmaceuticals Inc	Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado
GB201111705D0 (en)	2011-07-07	2011-08-24	Takeda Pharmaceutical	Compounds and their use
GB201111704D0 (en)	2011-07-07	2011-08-24	Takeda Pharmaceutical	Novel compounds
JO3115B1 (ar)	2011-08-22	2017-09-20	Takeda Pharmaceuticals Co	مركبات بيريدازينون واستخدامها كمثبطات daao
CA2872005A1 (en)	2012-05-08	2013-11-14	Forum Pharmaceuticals, Inc.	Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en)	2012-05-30	2012-07-11	Takeda Pharmaceutical	Therapeutic compounds
EP2953940B1 (en)	2013-02-07	2018-08-22	Heptares Therapeutics Limited	Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic m4 receptor agonists
CN105324372B (zh)	2013-06-21	2018-03-06	武田药品工业株式会社	作为前动力蛋白受体调节剂的1‑磺酰基哌啶衍生物
GB201314286D0 (en)	2013-08-08	2013-09-25	Takeda Pharmaceutical	Therapeutic Compounds
GB201318222D0 (en)	2013-10-15	2013-11-27	Takeda Pharmaceutical	Novel compounds
GB201320905D0 (en)	2013-11-27	2014-01-08	Takeda Pharmaceutical	Therapeutic compounds
TW201613864A (en)	2014-02-20	2016-04-16	Takeda Pharmaceutical	Novel compounds
GB201616839D0 (en)	2016-10-04	2016-11-16	Takeda Pharmaceutical Company Limited	Therapeutic compounds
GB201619514D0 (en)	2016-11-18	2017-01-04	Takeda Pharmaceuticals Co	Novel compounds
JP2021138648A (ja)	2020-03-04	2021-09-16	武田薬品工業株式会社	経口固形製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0984970B1 (en) *	1997-05-30	2003-11-19	Neurosearch A/S	Spiro-quinuclidine derivatives, their preparation and use
AR013184A1 (es) *	1997-07-18	2000-12-13	Astrazeneca Ab	Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) *	1999-01-15	1999-01-15	Astra Ab	New compounds

2002
- 2002-05-29 MX MXPA03010996A patent/MXPA03010996A/es active IP Right Grant
- 2002-05-29 CA CA002455341A patent/CA2455341A1/en not_active Abandoned
- 2002-05-29 NZ NZ529426A patent/NZ529426A/en unknown
- 2002-05-29 PT PT02731063T patent/PT1397366E/pt unknown
- 2002-05-29 JP JP2003500091A patent/JP2004532877A/ja active Pending
- 2002-05-29 AT AT02731063T patent/ATE353332T1/de not_active IP Right Cessation
- 2002-05-29 DK DK02731063T patent/DK1397366T3/da active
- 2002-05-29 EP EP02731063A patent/EP1397366B1/en not_active Expired - Lifetime
- 2002-05-29 IL IL15873502A patent/IL158735A0/xx unknown
- 2002-05-29 KR KR10-2003-7015462A patent/KR20040003021A/ko not_active Application Discontinuation
- 2002-05-29 WO PCT/SE2002/001031 patent/WO2002096912A1/en active IP Right Grant
- 2002-05-29 SI SI200230510T patent/SI1397366T1/sl unknown
- 2002-05-29 ES ES02731063T patent/ES2280538T3/es not_active Expired - Lifetime
- 2002-05-29 BR BR0210075-4A patent/BR0210075A/pt not_active IP Right Cessation
- 2002-05-29 DE DE60218032T patent/DE60218032T2/de not_active Expired - Fee Related
- 2002-05-29 CN CNB028110498A patent/CN1294136C/zh not_active Expired - Fee Related
2003
- 2003-11-11 ZA ZA200308779A patent/ZA200308779B/en unknown
- 2003-11-28 NO NO20035333A patent/NO20035333D0/no unknown
2004
- 2004-09-01 HK HK04106588A patent/HK1063787A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2280538T3 (es)	2007-09-16
MXPA03010996A (es)	2004-02-27
IL158735A0 (en)	2004-05-12
CA2455341A1 (en)	2002-12-05
DE60218032D1 (de)	2007-03-22
KR20040003021A (ko)	2004-01-07
WO2002096912A1 (en)	2002-12-05
CN1294136C (zh)	2007-01-10
BR0210075A (pt)	2004-08-17
NO20035333D0 (no)	2003-11-28
ATE353332T1 (de)	2007-02-15
DE60218032T2 (de)	2007-08-16
JP2004532877A (ja)	2004-10-28
EP1397366B1 (en)	2007-02-07
NZ529426A (en)	2005-07-29
EP1397366A1 (en)	2004-03-17
PT1397366E (pt)	2007-04-30
HK1063787A1 (en)	2005-01-14
CN1512995A (zh)	2004-07-14
DK1397366T3 (da)	2007-05-07
SI1397366T1 (sl)	2007-06-30

Publication	Publication Date	Title
EP1397366B1 (en)	2007-02-07	Novel ligand for nicotinic acetylcholine receptors useful in therapy
EP1213291B1 (en)	2004-12-01	Spiro [1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine for use in the treatment of psychotic and intellectual impairment disorders
US7417049B2 (en)	2008-08-26	Furyl compounds
EP1499616B1 (en)	2009-06-17	Heterocyclic compounds
EP0777671B1 (en)	2000-04-26	Spiro-azabicyclic compounds useful in therapy
AU2003224545B2 (en)	2009-08-13	Thienyl compounds
US6569865B2 (en)	2003-05-27	Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
EP1147114A1 (en)	2001-10-24	Novel aralkyl amines of spirofuropyridines useful in therapy
ZA200605027B (en)	2007-12-27	Nicotinic acetylcholine receptor ligands
ZA200604018B (en)	2007-11-28	4-Substituted imidazoles
AU2004285751B2 (en)	2008-07-24	Spirofuropyridine aryl derivatives
AU2002303064A1 (en)	2002-12-09	Novel ligand for nicotinic acetylcholine receptors useful in therapy
US20070244097A1 (en)	2007-10-18	Nicotinic AcetylcholineReceptor Ligands
US20070191422A1 (en)	2007-08-16	Nicotinic acetylcholine receptor ligands
MXPA01007162A (en)	2002-03-05	Novel aralkyl amines of spirofuropyridines useful in therapy